As our previous studies demonstrated that CD98hc is a promising target for tumor radiosensitization in HNSCC, we have used CD98hc-targeted antitumor immunotherapy in combination with experimental RT (Figure 1A). Here, SLC3A2 is linked to head and neck squamous cell carcinoma.